About Archon Bio
Archon Bio is a Healthcare company based in Seattle (United States) founded in 2023 by George Ueda, David Baker, James Lazarovits, and Lance Stewart. Archon Bio has raised $20 million across 1 funding round from investors including ARE, Duke University and Madrona. Its chief executive is James Lazarovits. Archon Bio offers products and services including Antibody Cage (AbC) and Generative AI Platform. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Formulation. Its legal entity is Archon Biosciences, Inc. Its competitors include Etcembly, SQALE, Plexymer, Maven Bio and Neuromathix and 1 more; 1 of its 6 listed competitors has raised funding.
Company details
Provider of computational platform to develop protein therapeutics. It combines antibodies with AI-generated proteins and Antibody Cage that leverages geometric engineering to control biodistribution and engagement to develop therapeutic targets.
- Headquarters Seattle, United States
- Founders George Ueda, David Baker, James Lazarovits, Lance Stewart
- SectorsHealthcare
- Email••••••••
- Website archon.bio
- Social LinkedIn
- Legal Name Archon Biosciences, Inc.
- Total Equity Funding$20M (USD)
in 1 rounds
- Latest Funding Round$20M (USD), Seed
Oct 2024
- InvestorsARE
& 6 more
Products & Services of Archon Bio
Archon Bio offers a comprehensive portfolio of products and services, including Antibody Cage (AbC) and Generative AI Platform.
Engineered proteins for targeted drug delivery and disease treatment.
AI system for creating tunable biologic structures in drug development.
Funding Insights of Archon Bio
Archon Bio has successfully raised a total of $20M through 1 strategic funding round. The most recent funding activity was a Seed round of $20 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20M
- Total Rounds 1
- Last Round Seed — $20M
- First Round $20M
(Oct 2024)
- Investors Count 7
All 1 funding rounds of Archon Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2024 | $20M | Seed | – | Madrona Venture Group |
7 investors in total: 7 institutional.
Investors in Archon Bio
Archon Bio has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Duke University and Madrona.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investing in AI, biotech, and technology sectors, focusing on seed and early stages in Seattle and beyond. | – | madrona.com | - | |
Investments in multiple sectors are made by Sahsen Ventures. | – | sahsen.com | Seattle, United States | |
Early-stage venture capital is provided to US companies across sectors. | – | wrfseattle.org | Seattle, United States | |
Pack Ventures is involved in unspecified business activities. | – | packvc.com | - | |
Cornucopian Capital is focused on health-focused venture capital investments. | – | cornucopiancapital.com | - | |
Multiple courses and degrees across diversified streams are offered. | 1838 | duke.edu | United States | |
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States |
Investor details for Archon Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Archon Bio
4 people are tracked at Archon Bio (4 in leadership).
| Name | Role | Group |
|---|---|---|
George Ueda | Co-Founder & CTO | Leadership |
David Baker | Co-Founder | Leadership |
James Lazarovits | Co-Founder & CEO | Leadership |
Lance Stewart | Co-Founder | Leadership |
Complete people profiles for Archon Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Archon Bio
2 dated milestones of Archon Bio across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Archon Bio is founded.
- Funding First funding round of $20.0M.
Competitors of Archon Bio
Archon Bio has 6 listed competitors in our database, 1 of them funded. They include Etcembly, SQALE, Plexymer, Maven Bio and Neuromathix, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| etcembly.io | 2020 | Harwell, United Kingdom | $12.66M | – | Provider of AI-based platform to engineer novel T cell receptors for cancer immunotherapy | |
| sqale.ai | 2023 | Copenhagen, Denmark | – | – | Provides bioprocess optimization services for microalgae and precision fermentation companies. | |
| plexymer.com | 2021 | Plainfield, United States | – | – | Develops custom polymer excipients using AI and robotics for pharmaceutical proteins. | |
| mavenbio.io | 2024 | Boston, United States | – | – | Provides AI tools for BioPharma research, workflows, and strategic insights. | |
| neuromathix.com | 2001 | Brisbane, Australia | – | – | Offers decision support software for personalized healthcare models based on patient data. | |
| sprectroo.com | 2022 | Santa Clara, United States | – | – | Sprectroo is an AI-driven platform for drug derivatization and repurposing. |
Detailed competitors of Archon Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Archon Bio
The website of Archon Bio (archon.bio) receives about 3.2K visits a month.
- Monthly visits3.2K
▲ 35.9% vs previous month
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Archon Bio (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Archon Bio
Complete news archive for Archon Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Archon Bio
Archon Bio was founded in 2023 and raised its 1st funding round 1 year after it was founded.
Archon Bio is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
James Lazarovits is the current CEO of Archon Bio. They have also founded this company.
Archon Bio is a funded company, having raised a total of $20M across 1 funding round to date. The company's 1st funding round was a Seed of $20M, raised on Oct 2024.
Provider of computational platform to develop protein therapeutics. It combines antibodies with AI-generated proteins and Antibody Cage that leverages geometric engineering to control biodistribution and engagement to develop therapeutic targets.
Archon Bio offers Antibody Cage (AbC) and Generative AI Platform.
Archon Bio has 7 investors. Key investors include ARE, Duke University, Madrona, Sahsen Ventures, and Washington Research Foundation.
Archon Bio operates through Archon Biosciences, Inc..